103 related articles for article (PubMed ID: 19470723)
1. Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
Khanna C; Gordon I
Clin Cancer Res; 2009 Jun; 15(11):3645-7. PubMed ID: 19470723
[TBL] [Abstract][Full Text] [Related]
2. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
4. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous mast cell tumours in dogs.
Kupfer J
Vet Rec; 2010 Mar; 166(13):407-8. PubMed ID: 20348476
[No Abstract] [Full Text] [Related]
6. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
Stanclift RM; Gilson SD
J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
[TBL] [Abstract][Full Text] [Related]
7. Cancer drug approved for dogs.
J Am Vet Med Assoc; 2009 Jul; 235(2):139. PubMed ID: 19610240
[No Abstract] [Full Text] [Related]
8. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
de Vos J; Ramos Vega S; Noorman E; de Vos P
Vet Comp Oncol; 2012 Sep; 10(3):206-13. PubMed ID: 22236048
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
11. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
12. Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor.
Kim JH; Yoon H; Yoon HY; Eom K; Sung HJ; Kim JH
Can Vet J; 2018 Apr; 59(4):367-372. PubMed ID: 29606721
[TBL] [Abstract][Full Text] [Related]
13. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
[TBL] [Abstract][Full Text] [Related]
15. Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia.
Pérez ML; Culver S; Owen JL; Dunbar M; Kow K; Breen M; Milner RJ
Anticancer Drugs; 2013 Nov; 24(10):1098-103. PubMed ID: 23995854
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors in veterinary oncology practice.
London CA
Vet Clin North Am Small Anim Pract; 2014 Sep; 44(5):893-908. PubMed ID: 25174906
[TBL] [Abstract][Full Text] [Related]
18. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S; Argyle DJ
Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
Flesner BK; Fletcher JM; Smithee T; Boudreaux B
J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
